VIP bone and cartilage research examines the skeletal effects of vasoactive intestinal peptide signaling through VPAC receptors expressed in bone and cartilage tissues. The VIP research cluster covers the vascular, immune, neural, and gastrointestinal biology of VIP. This article extends the analysis into the skeletal compartment where VPAC receptor expression supports effects on bone remodeling, cartilage biology, and joint inflammation.
VIP Bone and Cartilage Research: Skeletal VPAC Studies
VIP · Published April 24, 2026 · Updated May 18, 2026 · 8 min read
Quick Answer
VIP bone and cartilage research examines skeletal VPAC receptor biology and osteoporosis models in rodent skeletal research. Studies measure bone mineral density, osteoclast and osteoblast activity, cartilage matrix biomarkers, and VPAC1/VPAC2 signaling in bone tissue across standardized skeletal research protocols. For research use only, not for human consumption.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
- VPAC Receptor in Bone and Cartilage
- Osteoblast Research
- Osteoclast Research
- Osteoporosis Model Research
- Chondrocyte and Cartilage Research
- Joint Inflammation Research
- Bone Marrow and Hematopoiesis
- VIP and Mechanical Loading
- Research Design for Bone and Cartilage Studies
- Research Peptide Referenced
- Related Research Reading
- Related Research Articles
- Explore Related Products
- Frequently Asked Questions
- Glossary
Frequently Asked Questions
What is VIP in research contexts?
+
VIP (vasoactive intestinal peptide) is an endogenous 28-amino-acid neuropeptide of the secretin/glucagon superfamily. It is studied in preclinical models for vasodilation, immune modulation, circadian rhythm regulation, and pulmonary smooth muscle research through VPAC1 and VPAC2 receptor signaling.
How does VIP affect bone biology in research?
+
VPAC1 and VPAC2 receptors are expressed on osteoblasts, osteoclasts, and chondrocytes. VIP modulates bone remodeling through cAMP signaling, supporting osteoblast differentiation and modulating osteoclast activity in osteoporosis and bone repair research models.
What skeletal endpoints are measured in VIP research?
+
Endpoints include bone mineral density (DEXA, micro-CT), bone microarchitecture parameters, osteoblast and osteoclast counts on histology, biochemical bone turnover markers, and biomechanical strength testing in osteoporosis and fracture repair models.
Is VIP approved for human use?
+
Glossary
Key terms used in this article.
- VPAC1
- Vasoactive intestinal peptide receptor 1, broadly distributed, mediating immune and gastrointestinal effects of VIP.
- VPAC2
- Vasoactive intestinal peptide receptor 2, enriched in the suprachiasmatic nucleus and lung, involved in circadian and pulmonary signaling.
- Suprachiasmatic Nucleus (SCN)
- The hypothalamic master circadian pacemaker, where VPAC2 signaling is essential for synchronizing rhythmic neuronal activity.
- Vasodilation
- Widening of blood vessels resulting from relaxation of vascular smooth muscle, often mediated by nitric oxide or VIP signaling.
- Neuropeptide
- A peptide produced and released by neurons that acts as a signaling molecule in the nervous system.
- Osteoblast
- A bone-forming cell that synthesizes the protein matrix of bone and contributes to its mineralization.
- Osteoclast
- A multinucleated bone-resorbing cell that breaks down bone matrix as part of bone remodeling.
More from the Blog
Continue exploring research insights and updates.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
